Additive intraocular pressure-lowering effect of dorzolamide 1%/timolol 0.5% fixed combination on prostaglandin monotherapy in patients with normal tension glaucoma

Clinical Ophthalmology

Volumn 5, Issue 1, 2011, Pages 1515-1520

  Mizoguchi, Takanori ^a   Ozaki, Mineo ^b   Wakiyama, Harumi ^a,c   Ogino, Nobuchika ^a  

^a Mizoguchi Eye Clinic   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

^c JAPANESE RED CROSS NAGASAKI GENBAKU HOSPITAL   (Japan)

Author keywords

Dorzolamide 1 timolol 0.5 fixed combination; Fixed combination; IOP lowering effect; Normal tension glaucoma; Prostaglandin

Indexed keywords

DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; LEUPRORELIN; PROSTAGLANDIN; TAFLUPROST; TRAVATANZ; TRAVOPROST; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLURRED VISION; CASE CONTROL STUDY; CLINICAL ARTICLE; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; EVENING DOSAGE; EYE IRRITATION; FEMALE; HUMAN; INTRAOCULAR PRESSURE; LOW TENSION GLAUCOMA; MALE; MONOTHERAPY; MORNING DOSAGE; OCULAR PRURITUS; PROSPECTIVE STUDY;

EID: 81055140835     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/opth.s24058     Document Type: Article

References (20)

1. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126:498-505.
2. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126:487-497.
3. Rulo AH, Greve EL, Geijssen HC, Hoyng PF. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. Ophthalmology. 1996;103: 1276-1282.
4. Drance SM, Crichton A, Mills RP. Comparison of the effect of latanoprost 0.005% and timolol 0.5% on the calculated ocular perfusion pressure in patients with normal-tension glaucoma. Am J Ophthalmol. 1998;125:585-592.
5. Harris A, Migliardi R, Rechtman E, Cole CN, Yee AB, Garzozi HJ. Comparative analysis of the effects of dorzolamide and latanoprost on ocular hemodynamics in normal tension glaucoma patients. Eur J Ophthalmol. 2003;13:24-31.
6. Tomita G, Araie M, Kitazawa Y, Tsukahara S. A three-year prospective, randomized and open comparison between latanoprost and timolol in Japanese normal-tension glaucoma patients. Eye (Lond). 2004;18:984-989.
7. Driks MS, Noecker RJ, Earl M, Roh S, Silverstein SM, Williams RD. A 3-month clinical trial comparing the IOP-lowering eff icacy of bimatoprost and latanoprost in patients with normal-tension glaucoma. Adv Ther. 2006;23:385-394.
8. Kiuchi T, Motoyama Y, Oshika T. Influence of ocular hypotensive eyedrops on intraocular pressure fluctuation with postural change in eyes with normal-tension glaucoma. Am J Ophthalmol. 2007;143:693-695.
9. Quaranta L, Pizzolante T, Riva I, et al. Twenty-four-hour intraocular pressure and blood pressure levels with bimatoprost versus latanoprost in patients with normal-tension glaucoma. Br J Ophthalmol. 2008;92:1227-1231.
10. Suh MH, Park KH, Kim DM. Effect of travoprost on intraocular pressure during 12 months of treatment for normal-tension glaucoma. Jpn J Ophthalmol. 2009;53:18-23.
11. Kuwayama Y, Komemusi S. Intraocular pressure lowering effect of 0.0015% tafluprost as compared to placebo in patients with normal tension glaucoma: randomized, double-blind, multicenter, phase III study. J Jpn Ophthalmol Soc. 2010;114:436-443. Japanese.
12. Ang GS, Kersey JP, Sheptone L, Broadway DC. The effect of travoprost on daytime intraocular pressure in normal tension glaucoma: a randomised controlled trial. Br J Ophthalmol. 2008;92: 1129-1133.
13. Konstas A, Kozobolis VP, Lallos N, Christodoulakis E, Stewart JA, Stewart WC. Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/timolol maleate 0.5% and dorzolamide 2%/timolol maleate 0.5%. Eye (Lond). 2004;18: 1264-1269.
14. Choudhri S, Wand M, Shields MB. A comparison of dorzolamidetimolol combination versus the concomitant drugs. Am J Ophthalmol. 2000;130:832-833.
15. Konstas AG, Mikropoulos D, Dimopoulos AT, Moumtzis G, Nelson LA, Stewart WC. Second-line therapy with dorzolamide/timolol or latanoprost/ timolol fixed combination versus adding dorzolamide/timolol fixed combination to latanoprost monotherapy. Br J Ophthalmol. 2008;92:1498-1502.
16. Strohmaier K, Snyder E, DuBiner H, Adamsons I. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group. Ophthalmology. 1998;105:1936-1944.
17. Hutzelmann J, Owens S, Shedden A, Adamsons I, Vargas E. Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group. Br J Ophthalmol. 1998;82:1249-1253.
18. Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140:598-606.
19. Okeke CO, Quigley HA, Jampel HD, et al. Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study. Ophthalmology. 2009;116:191-199.
20. Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003; 12:393-398.